Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

Inclusion Criteria (for HIV #1, HIV #2) :

• 19 years old or older, HIV-1 infected person who have voluntarily agreed toparticipate in the study.

• Have been taking antiviral medications stably for at least one month at the time ofscreening.

• Have a CD4+ T-cell count measured before enrollment.

• Do not have AIDS-defining diseases (excluding oral thrush) or acute/uncontrolledopportunistic infection at the time of enrollment.

• Do not have uncontrolled chronic medical conditions other than HIV infection.

Inclusion Criteria (for non-HIV) :

• 50 years old or older who have voluntarily agreed to participate in the study.

• Do not have uncontrolled chronic medical conditions

Exclusion Criteria:

• Have received any type of zoster vaccine within 1 year.

• Have been diagnosed with chickenpox or shingles within 12 months.

• Have a history of severe allergy to any of the components of Shingrix vaccine.

• Have a acute medical condition at the time of screening.

• Unable to be evaluated for adverse events via telephone contact after vaccination.

• Pregnant (including those planning to become pregnant) or lactating women.

• Those who have received chemotherapy or radiotherapy within 6 months prior to thefirst vaccine dose.

• Chronic administration of immunosuppressive or other immune-modifying drugs within 6months prior to ther first vaccine dose.

• Administration of immunoglobulins, and/or any blood products within 3 monthspreceding the first dose of study vaccine

• Have a medical condition that makes receiving an intramuscular injection medicallycontraindicated.

• Have a disease or condition that may affect the immunogenicity or safety of thevaccine.

• Receiving any other vaccine within 14 days prior to and 14 days after receiving thestudy vaccine.

• Participate in a clinical trial that involves other investigational product ordevice during the course of the study.

• Any other person who, in the opinion of the investigator, is unsuitable for immuneresponse assessment.